{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:27:16Z","timestamp":1781828836219,"version":"3.54.5"},"reference-count":80,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K12HL143886-02"],"award-info":[{"award-number":["5K12HL143886-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>There is a high incidence and prevalence of hepatitis C viral infection in persons with or without substance use disorders (SUDs) in the Middle East and North Africa (MENA) region, but only a small number receive comprehensive care. Highly effective direct-acting antiviral (DAA) medications are available at substantially lower costs; however, complete elimination of the hepatitis C virus (HCV) can only be achieved if integrated care strategies target those at highest risk for HCV infection and transmission and improve access to care. Due to the high prevalence of SUD in the MENA region, strategies to eliminate HCV must focus on integrated healthcare across multiple subspecialties, including addiction medicine, psychiatry, infectious diseases, hepatology, and social work. In this invited manuscript, we review the epidemiology of HCV in the MENA region and highlight intervention strategies to attain the WHO\u2019s goal of HCV eradication by 2030.<\/jats:p>","DOI":"10.3390\/v13071363","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T21:56:51Z","timestamp":1626299811000},"page":"1363","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies"],"prefix":"10.3390","volume":"13","author":[{"given":"Jag H.","family":"Khalsa","sequence":"first","affiliation":[{"name":"Medical Consequences of Drug Abuse and Infections Branch, Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA"},{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Mathur","sequence":"additional","affiliation":[{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bpg.2012.09.009","article-title":"Natural history of acute and chronic hepatitis C","volume":"26","author":"Maasoumy","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000500963","article-title":"Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications","volume":"35","author":"Sandmann","year":"2019","journal-title":"Visc. Med."},{"key":"ref_3","unstructured":"World Health Organization (2017). Global Hepatitis Report, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/global-hepatitis-report-2017."},{"key":"ref_4","unstructured":"The Polaris Observatory HCV Collaborators (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol., 2, 161\u2013176."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Harfouche, M., Chemaitelly, H., Kouyoumjian, S.P., Mahmud, S., Chaabna, K., Al-Kanaani, Z., and Abu-Raddad, L.J. (2017). Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187177"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14218\/JCTH.2017.00067","article-title":"Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review","volume":"6","author":"Axley","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/JHC.S164568","article-title":"Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: Exposing an overlooked presentation of liver cancer","volume":"5","author":"Dandachi","year":"2018","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: A systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Vutien, P., Jin, M., Le, M.H., Nguyen, P., Trinh, S., Huang, J.F., Yu, M.L., Chuang, W.L., and Nguyen, M.H. (2017). Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183851"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e029516","DOI":"10.1136\/bmjopen-2019-029516","article-title":"Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment-ADVANCE HCV protocol study","volume":"9","author":"Inglis","year":"2019","journal-title":"BMJ Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2011055","DOI":"10.1001\/jamanetworkopen.2020.11055","article-title":"Association of Direct-Acting Antiviral Treatment with Mortality among Medicare Beneficiaries with Hepatitis C","volume":"3","author":"Kalidindi","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Torrens, M., Soyemi, T., Bowman, D., and Schatz, E. (2020). Beyond clinical outcomes: The social and healthcare system implications of hepatitis C treatment. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05426-4"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jgh.14466","article-title":"Burden of hepatitis C virus infection in India: A systematic review and meta-analysis","volume":"34","author":"Goel","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S2468-1253(16)30031-0","article-title":"Hepatitis B and hepatitis C in southeast and southern Asia: Challenges for governments","volume":"1","author":"Wait","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.drugpo.2016.03.002","article-title":"Drug policy and harm reduction in the Middle East and North Africa: The role of civil society","volume":"31","author":"Aaraj","year":"2016","journal-title":"Int. J. Drug Policy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.3748\/wjg.v24.i27.3038","article-title":"Systematic overview of hepatitis C infection in the Middle East and North Africa","volume":"24","author":"Chaabna","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep4.1310","article-title":"Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2500 Prevalence Measures, Including 49 Million Tests","volume":"3","author":"Chemaitelly","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/jmv.24921","article-title":"Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns","volume":"90","author":"Mahmud","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annepidem.2018.03.007","article-title":"Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: A systematic synthesis","volume":"28","author":"Mahmud","year":"2018","journal-title":"Ann. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mohamoud, Y.A., Mumtaz, G.R., Riome, S., Miller, D., and Abu-Raddad, L.J. (2013). The epidemiology of hepatitis C virus in Egypt: A systematic review and data synthesis. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-288"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijid.2016.03.012","article-title":"Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence","volume":"46","author":"Mohamoud","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jvh.12476","article-title":"The present and future disease burden of hepatitis C virus infections with today\u2019s treatment paradigm\u2014Volume 3","volume":"22","author":"Sibley","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40249-019-0528-6","article-title":"Epidemiology and management of hepatitis C virus infections in immigrant populations","volume":"8","author":"Coppola","year":"2019","journal-title":"Infect. Dis. Poverty"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/1469-0691.12021","article-title":"Infectious diseases in Iran: A bird\u2019s eye view","volume":"18","author":"Askarian","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s15010-011-0236-z","article-title":"Hepatitis C virus infection in the Middle East and North Africa \u201cMENA\u201d region: Injecting drug users (IDUs) is an under-investigated population","volume":"40","author":"Ramia","year":"2012","journal-title":"Infection"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jvh.12475","article-title":"Historical epidemiology of hepatitis C virus (HCV) in select countries\u2014Volume 3","volume":"22","author":"Liakina","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_28","first-page":"44","article-title":"Hepatitis C virus (HCV) infection in Africa: A review","volume":"14","author":"Karoney","year":"2013","journal-title":"Pan Afr. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3748\/wjg.v24.i38.4330","article-title":"Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations","volume":"24","author":"Omran","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"180257","DOI":"10.1098\/rsos.180257","article-title":"The epidemiology of hepatitis C virus in Pakistan: Systematic review and meta-analyses","volume":"5","author":"Mahmud","year":"2018","journal-title":"R. Soc. Open Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ypmed.2009.04.014","article-title":"The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994\u20132004","volume":"49","author":"Holtzman","year":"2009","journal-title":"Prev. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1360-0443.2011.03765.x","article-title":"Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment","volume":"107","author":"Pouget","year":"2012","journal-title":"Addiction"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/aje\/kwn237","article-title":"Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place","volume":"168","author":"Hagan","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/ADT.0000000000000104","article-title":"Medical and behavioral approaches to engage people who inject drugs into care for hepatitis c virus infection","volume":"16","author":"Gonzalez","year":"2017","journal-title":"Addict. Disord. Their Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2893.2010.01411.x","article-title":"Integrated internist\u2014Addiction medicine\u2014Hepatology model for hepatitis C management for individuals on methadone maintenance","volume":"19","author":"Martinez","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and Safety of Sofosbuvir\/Velpatasvir in Patients with Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","article-title":"Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs","volume":"71","author":"Rosenthal","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/QAI.0b013e3181f9c0c9","article-title":"Epidemiologic links between drug use and HIV epidemics: An international perspective","volume":"55","author":"Beyrer","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mumtaz, G.R., Weiss, H.A., Thomas, S.L., Riome, S., Setayesh, H., Riedner, G., Semini, I., Tawil, O., Akala, F.A., and Wilson, D. (2014). HIV among people who inject drugs in the Middle East and North Africa: Systematic review and data synthesis. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001663"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.ijid.2009.11.032","article-title":"Seroprevalence of hepatitis C virus: The first population-based study from Iran","volume":"14","author":"Merat","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/add.14944","article-title":"The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa","volume":"115","author":"Mahmud","year":"2020","journal-title":"Addiction"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.13949","article-title":"Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework","volume":"39","author":"Day","year":"2019","journal-title":"Liver Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: A global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","article-title":"The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: A modelling study","volume":"4","author":"Trickey","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41575-020-00392-3","article-title":"Hepatitis C virus elimination: Laying the foundation for achieving 2030 targets","volume":"18","author":"Dore","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Martinez, I., Ryan, P., Valencia, J., and Resino, S. (2021). The Challenging Road to Hepatitis C Virus Eradication. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040611"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1093\/pubmed\/fdy115","article-title":"Implementation of a unique hepatitis C care continuum model in Rwanda","volume":"41","author":"Mathur","year":"2019","journal-title":"J. Public Health"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ali, S., Ur-Rehman, T., Ali, M., Haque, S., Rasheed, F., Lougher, E., Nawaz, M.S., and Paudyal, V. (2020). Improving access to the treatment of hepatitis C in low- and middle-income countries: Evaluation of a patient assistance programme. Int. J. Clin. Pharm.","DOI":"10.1007\/s11096-020-01202-1"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2468-1253(21)00012-1","article-title":"Decentralised hepatitis C testing and treatment in rural Cambodia: Evaluation of a simplified service model integrated in an existing public health system","volume":"6","author":"Zhang","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and Treatment Program to Eliminate Hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Beckwith, C.G., Kuo, I., Fredericksen, R.J., Brinkley-Rubinstein, L., Cunningham, W.E., Springer, S.A., Loeliger, K.B., Franks, J., Christopoulos, K., and Lorvick, J. (2018). Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197730"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/apc.2012.0269","article-title":"Health care and HIV testing experiences among Black men in the South: Implications for \u201cSeek, Test, Treat, and Retain\u201d HIV prevention strategies","volume":"27","author":"Doshi","year":"2013","journal-title":"AIDS Patient Care STDS"},{"key":"ref_58","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/M16-0065","article-title":"Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis","volume":"165","author":"Freiman","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciz273","article-title":"Hepatitis C Core Antigen Testing: Still an Effective Diagnostic Method for Global Elimination of Hepatitis C","volume":"70","author":"Mathur","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/00333549161310S214","article-title":"Improving Screening Methods for Hepatitis C among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012\u20132014","volume":"131","author":"Blackburn","year":"2016","journal-title":"Public Health Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcv.2012.04.003","article-title":"Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA","volume":"54","author":"Jewett","year":"2012","journal-title":"J. Clin. Virol"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e12620","DOI":"10.2196\/12620","article-title":"A Mobile Health Intervention to Improve Hepatitis C Outcomes among People with Opioid Use Disorder: Protocol for a Randomized Controlled Trial","volume":"8","author":"Hochstatter","year":"2019","journal-title":"JMIR Res. Protoc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1357633X18806651","article-title":"Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era","volume":"26","author":"Schulz","year":"2020","journal-title":"J. Telemed. Telecare"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ishizaki, A., Bouscaillou, J., Luhmann, N., Liu, S., Chua, R., Walsh, N., Hess, S., Ivanova, E., Roberts, T., and Easterbrook, P. (2017). Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2767-0"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Reipold, E.I., Trianni, A., Krakower, D., Ongarello, S., Roberts, T., Easterbrook, P., and Denkinger, C. (2017). Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: Results of a survey of end users and implementers. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2769-y"},{"key":"ref_67","unstructured":"Van Damme, P., Lavanchy, D., Hendrickx, G., Lodewyckx, I., and Vorsters, A. (2016). Innovative Financing into Hepatitis B and C Prevention and Treatment in Low and Middle Income Countries, IFPMA."},{"key":"ref_68","unstructured":"Swan, T., Chou, L., and Benzacar, A. (2015). Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries, Treatment Action Group."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Suthar, A.B., and Harries, A.D. (2015). A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001795"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13027-016-0071-z","article-title":"Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States","volume":"11","author":"Rosenthal","year":"2016","journal-title":"Infect. Agents Cancer"},{"key":"ref_71","first-page":"2381468318776634","article-title":"Population Health and Cost-Effectiveness Implications of a \u201cTreat All\u201d Recommendation for HCV: A Review of the Model-Based Evidence","volume":"3","author":"Cipriano","year":"2018","journal-title":"MDM Policy Pract."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation","volume":"65","author":"Martin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/M16-2887","article-title":"Toward Optimal Control of Hepatitis C Virus Infection in Persons with Substance Use Disorders","volume":"166","author":"Talal","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gountas, I., Sypsa, V., Blach, S., Razavi, H., and Hatzakis, A. (2018). HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202109"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/HMER.S212855","article-title":"Project ECHO Revisited: Propensity Score Analysis and HCV Treatment Outcomes","volume":"11","author":"Page","year":"2019","journal-title":"Hepat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000179","article-title":"The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): The use of direct-acting antivirals as treatment for prevention","volume":"10","author":"Martin","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1086\/591707","article-title":"Clinical outcomes of hepatitis C treatment in a prison setting: Feasibility and effectiveness for challenging treatment populations","volume":"47","author":"Maru","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Hajarizadeh, B., Grebely, J., Byrne, M., Marks, P., Amin, J., McManus, H., Butler, T., Cunningham, E.B., Vickerman, P., and Martin, N.K. (2021). Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): A prospective cohort study. Lancet Gastroenterol. Hepatol.","DOI":"10.1016\/S2468-1253(21)00077-7"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kwon, J.A., Chambers, G.M., Luciani, F., Zhang, L., Kinathil, S., Kim, D., Thein, H.H., Botha, W., Thompson, S., and Lloyd, A. (2021). Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245896"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1363\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:30:26Z","timestamp":1760164226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":80,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["v13071363"],"URL":"https:\/\/doi.org\/10.3390\/v13071363","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}